Anti-Aβ globulomer 5F7 antibodies

US8691224B2 · kind B2 · utility

Assignees

• Abb Vie Inc. · US
• Abb Vie Deutschland Gmbh & Co. KG · DE

Inventors

• Stefan Barghorn · Mannheim, DE
• Heinz Hillen · Herbrechtingen, DE
• Boris Labkovsky · Framingham, US
• Andreas Striebinger · Speyer, DE
• Patrick Keller · Darmstadt, DE
• Ulrich Ebert · Mannheim, DE

Key dates

• Filing date: Nov 30, 2006
• Grant date: Apr 8, 2014
• Expiry date: Dec 28, 2029

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/2821
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Anti-Aβ globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies.The present invention relates to anti-Aβ globulomer antibodies having a binding affinity to Aβ(20-42) globulomer that is greater than the binding affinity of the antibody to Aβ(1-42) globulomer, antigen-binding moieties thereof, hybridomas producing said antibodies, nucleic acids encoding said antibodies, vectors comprising said nucleic acids, host cells comprising said vectors, methods of producing said antibodies, compositions comprising said antibodies, therapeutic and diagnostic uses of said antibodies and corresponding methods relating to Alzheimer's disease and other amyloidoses.